Cargando…

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies that are approved for routine clinical use. The regulation of PD-L1 expression is complex, varies between different tumor types and o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zerdes, Ioannis, Matikas, Alexios, Bergh, Jonas, Rassidakis, George Z., Foukakis, Theodoros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107481/ https://www.ncbi.nlm.nih.gov/pubmed/29765155 http://dx.doi.org/10.1038/s41388-018-0303-3

Ejemplares similares

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
por: Zerdes, Ioannis, et al.
Publicado: (2020)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

PD-1 protein and gene expression as prognostic factors in early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2020)

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
por: Zhu, Yajing, et al.
Publicado: (2022)

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2021)

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2019)

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
por: Tzoras, Evangelos, et al.
Publicado: (2022)

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018)

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
por: Matikas, A, et al.
Publicado: (2019)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2017)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies
por: Milosevic, Jelena, et al.
Publicado: (2013)

Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
por: von Stedingk, Hans, et al.
Publicado: (2014)

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
por: Brandberg, Yvonne, et al.
Publicado: (2020)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1
por: Krutzek, Fabian, et al.
Publicado: (2023)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Pre-Column Derivatization HPLC Procedure for the Quantitation of Aluminium Chlorohydrate in Antiperspirant Creams Using Quercetin as Chromogenic Reagent
por: Kalogria, Eleni, et al.
Publicado: (2014)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
por: Matikas, Alexios, et al.
Publicado: (2015)

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
por: Atsaves, Vasileios, et al.
Publicado: (2019)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Programmed death-ligand 1 expression in rectal cancer
por: Jomrich, G., et al.
Publicado: (2016)

Status of programmed death-ligand 1 expression in sarcomas
por: Park, Hyung Kyu, et al.
Publicado: (2018)

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pl84kp3dfa0opg731d24vc7ocq